JEROME CANTOR
Osteopathic Medicine at 82 St, Brooklyn, NY
License number
New York 127276
Category
Osteopathic Medicine
Type
General Practice
Address
Address
258 82Nd St, Brooklyn, NY 11209
Phone
(718) 238-3415
Personal information
See more information about JEROME CANTOR at radaris.comName
Address
Phone
258 82Nd St, Brooklyn, NY 11209
5900 Arlington Ave APT 4H, Bronx, NY 10471
5900 Arlington Ave, Bronx, NY 10471
10230 Queens Blvd, Forest Hills, NY 11375
61 Nostrand Ave, Staten Island, NY 10314
Professional information
See more information about JEROME CANTOR at trustoria.com
Intratracheal Administration Of Lysozyme With Other Therapeutic Agents In The Prevention And Treatment Of Respiratory Disorders
Intratracheal Administration Of Lysozyme With Other Therapeutic Agents In The Prevention And Treatment Of Respiratory Disorders
US Patent:
7364888, Apr 29, 2008
Filed:
Jul 7, 2005
Appl. No.:
11/175332
Inventors:
Jerome Owen Cantor - Brooklyn NY, US
Bronislava Shteyngart - Brooklyn NY, US
Bronislava Shteyngart - Brooklyn NY, US
International Classification:
C12N 9/00
US Classification:
435183
Abstract:
The subject invention is directed to the prevention and treatment of respiratory disorders by intratracheal administration of an effective amount of lysozyme, either alone or in combination with other therapeutic agents. Applicable respiratory disorders include, but are not limited to, pulmonary emphysema, asthma, bronchitis, pneumonia, respiratory distress syndrome, bronchopulmonary dysplasia, interstitial fibrosis, cystic fibrosis, and neoplasia. The method is intended for a variety of mammals, including humans ranging from premature neonates to adults.
Measurement Of Elastic Fiber Breakdown Products In Sputum
Measurement Of Elastic Fiber Breakdown Products In Sputum
US Patent:
7166437, Jan 23, 2007
Filed:
Sep 24, 2002
Appl. No.:
10/253756
Inventors:
Jerome Owen Cantor - Brooklyn NY, US
Bronislava Shteyngart - Brooklyn NY, US
Bronislava Shteyngart - Brooklyn NY, US
International Classification:
G01N 33/53, G01N 33/537, G01N 30/90, G01N 24/00, G01N 33/557, G01N 33/543, C12N 9/00
US Classification:
435 71, 435 792, 435183, 436162, 436173, 436517, 436518
Abstract:
The subject invention is directed to the measurement of elastic fiber breakdown products in human sputum obtained from patients with emphysema and other lung diseases. Measurement of elastic fiber breakdown products may be used to monitor the progression of lung disease or to assess the efficacy of a treatment for lung disease. Such breakdown products are associated with lung injury resulting from degradation of lung elastic fibers. This process may occur in emphysema and other inflammatory disease of the lung where excess amounts of elastase are secreted by inflammatory cells. The methods for measuring elastin breakdown products in certain tissue fluids (i. e. blood, urine, bronchoalveolar lavage fluid) are well known to the art but have not been previously applied to sputum samples. The use of sputum has several advantages over other fluids, including greater specificity and ease of procurement.
Intratracheal Administration Of Endothelin-Suppressing Agents For The Treatment Of Respiratory Disorders
Intratracheal Administration Of Endothelin-Suppressing Agents For The Treatment Of Respiratory Disorders
US Patent:
2009001, Jan 8, 2009
Filed:
Jul 5, 2007
Appl. No.:
11/824860
Inventors:
Jerome Cantor - Brooklyn NY, US
Tapan Bhavsar - Queens NY, US
Sandra Reznik - Larchmont NY, US
Tapan Bhavsar - Queens NY, US
Sandra Reznik - Larchmont NY, US
International Classification:
A61K 31/70, A61P 11/00
US Classification:
514 25
Abstract:
The subject invention is directed to the treatment of respiratory disorders by intratracheal administration of an effective amount of an agent that suppresses the activity of endothelin. Such agents may take the form of: 1) an endothelin-converting enzyme (ECE) inhibitor such as phosphoramidon, or 2) an endothelin receptor antagonist such as bosentan, tezosentan, sitaxsentan, atrasentan, darusentan, clazosentan, or BQ-123. Respiratory disorders include emphysema, asthma, bronchitis, bronchiectasis, pneumonia, adult respiratory distress syndrome, neonatal respiratory distress syndrome, bronchopulmonary dysplasia, interstitial fibrosis, cystic fibrosis, persistent pulmonary hypertension of the newborn, and neoplasia. The treatment is intended for a variety of mammals, such as premature neonates to adult humans.
Method For Treating Respiratory Disorders Associated With Pulmonary Elastic Fiber Injury
Method For Treating Respiratory Disorders Associated With Pulmonary Elastic Fiber Injury
US Patent:
2002008, Jul 4, 2002
Filed:
May 23, 2001
Appl. No.:
09/863849
Inventors:
Jerome Cantor - Brooklyn NY, US
Jing-wen Kuo - Wakefield MA, US
Paul Mihalko - Fremont CA, US
Dan Sachs - Boston MA, US
Gerard Turino - New York NY, US
Jing-wen Kuo - Wakefield MA, US
Paul Mihalko - Fremont CA, US
Dan Sachs - Boston MA, US
Gerard Turino - New York NY, US
International Classification:
A61K031/737, A61K031/728, A61K031/727, A61K009/00, A61L009/04
US Classification:
514/054000, 514/056000, 424/043000
Abstract:
The present invention relates generally to the field of respiratory therapeutics, and in particular to the treatment of disorders of the lung matrix caused by damage to the elastic fibers of the lung matrix. More specifically, methods and materials are disclosed for the delivery to the lungs of polysaccharides, derivatives thereof and/or drug conjugates, used in the treatment and/or prevention of pulmonary disorders.
Lectins As Anti-Fibrotic Agents
Lectins As Anti-Fibrotic Agents
US Patent:
7026287, Apr 11, 2006
Filed:
May 12, 2003
Appl. No.:
10/435549
Inventors:
Jerome Owen Cantor - Brooklyn NY, US
Bronislava Shteyngart - Brooklyn NY, US
Bronislava Shteyngart - Brooklyn NY, US
International Classification:
A61K 38/16
US Classification:
514 8, 514 2, 5303875, 530395, 424725
Abstract:
The subject invention is directed to the treatment of tissue fibrosis by administration of an effective amount of lectin. Fibrosis herein refers to the accumulation of extracellular matrix constituents that occurs following trauma, inflammation, tissue repair, immunological reactions, cellular hyperplasia, and neoplasia. Examples of tissue fibrosis include, but are not limited to, pulmonary fibrosis, cirrhosis of the liver, skin scars and keloids, adhesions, fibromatosis, atherosclerosis, and amyloidosis. The treatment is intended for a variety of mammals, including humans.
Synthesis Of 1,3,6-Trisubstituted-2-Carboxyquinol-4-Ones As Selective Et A Antagonists And Their Use As Medicaments
Synthesis Of 1,3,6-Trisubstituted-2-Carboxyquinol-4-Ones As Selective Et A Antagonists And Their Use As Medicaments
US Patent:
2009014, Jun 4, 2009
Filed:
Sep 10, 2008
Appl. No.:
12/283215
Inventors:
Ralph Anthony Stephani - Mamaroneck NY, US
Hardik Jitendra Patel - Flushing NY, US
Sandra Eve Reznik - Larchmont NY, US
Jerome Owen Cantor - Brooklyn NY, US
Hardik Jitendra Patel - Flushing NY, US
Sandra Eve Reznik - Larchmont NY, US
Jerome Owen Cantor - Brooklyn NY, US
International Classification:
A61K 31/4709, A61P 9/00, A61P 11/00, A61P 1/00, A61P 7/00
US Classification:
514312
Abstract:
The invention discloses the composition and preparation of various 1,3,6-trisubstituted-2-carboxy-quinol-4-ones of the formula 1 where R is H, alkyl, haloalkyl or hydroxyalkyl, R′ is alkyl, nitro, halogen or NR′″ where R′″ is alkyl or cycloalkyl, and R″ is H or alkyl. The composition of the invented compounds as methods of antagonizing the action of endothelin-1 to treat cardiovascular, pulmonary diseases and obstetric disorders and preterm labor and preeclampsia in mammals is disclosed.